[Link to your dedicated page about compounding standards and safety] Wilding, J
Key Insight: The contribution to total spend on GLP-1s for members with obesity without a diabetes diagnosis has grown significantly, now constituting almost 16.5% of spend on these drugs compared to 11% in 2022 and just 4% in 2020
According to 2023 research, Mounjaro is very effective for weight loss, with people losing Here, we compare the most popular GLP-1 medications on price*, dose frequency, and FDA approval
If your client has Type 2 diabetes or moderate-to-severe sleep apnea, they actually do not qualify for the Bridge program because their regular Part D or MAPD plan should already cover their GLP-1 medication
Navigate Diet Trends With Science: Critically evaluate popular diet myths and provide evidence-based guidance for lifelong healthy habits
12-14 As many patients with T2DM are overweight or obese, a drug that can help patients achieve any amount of weight loss is often welcomed by patients and physicians alike